Strona główna・Stock List・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

63.73 2.62

Buy Sell

Overview

Share price change

24h

Current

Min

62.02

Max

64.28

Key metrics
By Trading Economics
Income	3M -102M
EPS	-1.17
Employees	358
EBITDA	-7.6M -112M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+21.88% upside

Dividends
By Acuity
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	811M 6.4B
Previous open	61.11
Previous close	63.73

News Sentiment

By Acuity

68%

32%

299 / 340 Ranking in Healthcare

Xenon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 sie 2026, 19:46 UTC

News

Xenon Pharmaceuticals announced equity inducement grants totaling 32,758 share options and 19,013 RSUs. Shares are lower during Monday's session, near the one-month range's low.

31 lip 2026, 23:01 UTC

News

Xenon Pharmaceuticals shares are lower in after-market hours following the announcement of inducement grants for eleven new non-officer employees.

30 lip 2026, 13:36 UTC

Xenon Pharmaceuticals Inc shares are higher in pre-market trading, reflecting a broader market recovery despite rising treasury yields and geopolitical tensions.

29 lip 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are little changed after-market, continuing a trend of three consecutive lower daily finishes amid a broader decline in U.S. equities.

28 lip 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are lower today, pulling back from earlier gains amid notable volatility and no specific news to explain the movement.

27 lip 2026, 16:06 UTC

Xenon Pharmaceuticals Inc shares are lower today amid a broader market decline linked to falling crude oil prices and eased geopolitical tensions.

24 lip 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting positive momentum since Friday's close, despite no specific news identified.

23 lip 2026, 23:51 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the decline.

22 lip 2026, 23:11 UTC

Xenon Pharmaceuticals Inc shares declined in after-market trading amid broader market volatility, influenced by geopolitical tensions and rising crude oil prices.

21 lip 2026, 19:36 UTC

Xenon Pharmaceuticals shares are higher, supported by overall market strength and advances in biotechnology stocks, despite no specific company news identified.

20 lip 2026, 22:02 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, following notable volatility and no specific news identified. The stock remains above its 20-day moving average.

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

21.88% upside

12 Months Forecast

Average 75.88 USD 21.88%

High 86 USD

Low 63 USD

Based on 12 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Xenon Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

299 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.